DRKS00033077已完成不适用
Feasibility and Safety of Pressurized Intraperitoneal Aerosol Chemotherapy delivered with a multi-directional nebulizer (MDN-PIPAC)
Klinikum Dortmund0 个研究点目标入组 21 人开始时间: 2023年11月20日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 21
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- one 至 one（—）
- 性别
- All
入选标准
- •All patients who had the chemotherapy drugs administered into the abdominal cavity with the MDN device (multi-directional nebulizer) as part of a PIPAC treatment for peritoneal carcinosis at Klinikum Dortmund between 2022 and 2023.
排除标准
- •Patients who objected to retrospective data analysis.
研究者
相似试验
招募中
不适用
The Safety And Feasibility of Pressurised Intraperitoneal Aerosol Chemotherapy (PIPAC) in the treatment of Unresectable Disseminated Peritoneal MalignancyACTRN12618001017213Department of Surgery, University of Adelaide, TQEH112
尚未招募
1 期
Proof of concept: can pressurised intraperitoneal aerosol chemotherapy with oxaliplatin (PIPAC-O) be added to standard treatment for resectable high-risk gastric cancer patients?Cancer - StomachGastric cancerACTRN12620001228976The Queen Elizabeth Hospital10
招募中
1 期
Implementation and evaluation of Pressurized Intrathoracic Aerosol Chemotherapy (PITAC) for the treatment of patients with malignant pleural effusion. A Danish phase IMalignant pleural effusionCTIS2023-503297-20-00Odense University Hospital20
已完成
Unknown
Effect of intravenous lignocaine in preventing post operative sorethroat, an intervention studyCTRI/2023/06/053564COMMAND HOSPITAL AIRFORCE BANGALORE168
进行中（未招募）
不适用
Feasibility study of hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with stage III or only pleural stage IV ovarian carcinoma in first line therapy. - HIPEC-ovarian carcinomaInclusion criteria :1. Histologically confirmed ovarian carcinoma or primary peritoneal carcinoma or Fallopian tube carcinoma.2. FIGO stage III disease or only pleural stage IV disease3. Age less than 65 years4. ECOG performance status 0-1.5. Adequate bone marrow, hepatic and renal functions.6. No serious cardiac or respiratory illnessEUCTR2009-009467-59-BEInstitut Jules Bordet